Natalie Y.L. Ngoi

1.8k total citations
70 papers, 919 citations indexed

About

Natalie Y.L. Ngoi is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Natalie Y.L. Ngoi has authored 70 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 29 papers in Molecular Biology and 24 papers in Reproductive Medicine. Recurrent topics in Natalie Y.L. Ngoi's work include Ovarian cancer diagnosis and treatment (24 papers), PARP inhibition in cancer therapy (21 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Natalie Y.L. Ngoi is often cited by papers focused on Ovarian cancer diagnosis and treatment (24 papers), PARP inhibition in cancer therapy (21 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Natalie Y.L. Ngoi collaborates with scholars based in Singapore, United States and South Korea. Natalie Y.L. Ngoi's co-authors include David S.P. Tan, Timothy A. Yap, Deepak Bhamidipati, Shazib Pervaiz, Valerie Heong, Boon Cher Goh, Guang Peng, Marie‐Véronique Clement, Stephen Jun Fei Chong and Matthew S. Davids and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Natalie Y.L. Ngoi

62 papers receiving 905 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Natalie Y.L. Ngoi Singapore 17 506 428 192 146 131 70 919
Marilena Di Napoli Italy 16 433 0.9× 331 0.8× 374 1.9× 187 1.3× 140 1.1× 64 1.0k
Anselmo Papa Italy 12 335 0.7× 313 0.7× 139 0.7× 160 1.1× 73 0.6× 25 675
Matin Sheriff United Kingdom 16 551 1.1× 364 0.9× 316 1.6× 170 1.2× 117 0.9× 33 1.0k
Shelly Seward United States 15 390 0.8× 298 0.7× 246 1.3× 157 1.1× 59 0.5× 34 898
Yoshimichi Tanaka Japan 16 269 0.5× 350 0.8× 280 1.5× 194 1.3× 87 0.7× 45 850
Masanori Kanemura Japan 18 309 0.6× 415 1.0× 269 1.4× 193 1.3× 86 0.7× 37 920
Koji Yamanoi Japan 12 464 0.9× 290 0.7× 164 0.9× 228 1.6× 362 2.8× 72 946
Andrea E. Wahner Hendrickson United States 15 839 1.7× 633 1.5× 405 2.1× 157 1.1× 164 1.3× 55 1.3k
Katherine C. Kurnit United States 15 294 0.6× 327 0.8× 383 2.0× 231 1.6× 88 0.7× 48 987
Satoshi Tsunetoh Japan 15 243 0.5× 280 0.7× 235 1.2× 159 1.1× 68 0.5× 32 715

Countries citing papers authored by Natalie Y.L. Ngoi

Since Specialization
Citations

This map shows the geographic impact of Natalie Y.L. Ngoi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalie Y.L. Ngoi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalie Y.L. Ngoi more than expected).

Fields of papers citing papers by Natalie Y.L. Ngoi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalie Y.L. Ngoi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalie Y.L. Ngoi. The network helps show where Natalie Y.L. Ngoi may publish in the future.

Co-authorship network of co-authors of Natalie Y.L. Ngoi

This figure shows the co-authorship network connecting the top 25 collaborators of Natalie Y.L. Ngoi. A scholar is included among the top collaborators of Natalie Y.L. Ngoi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natalie Y.L. Ngoi. Natalie Y.L. Ngoi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ngoi, Natalie Y.L., Chel Hun Choi, Diana Lim, et al.. (2025). Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. Clinical Cancer Research. 31(18). 3907–3915. 2 indexed citations
2.
Ngoi, Natalie Y.L., et al.. (2025). Drugging the DNA damage response in the clinic: going beyond PARP. Expert Review of Anticancer Therapy. 26(1). 43–58. 1 indexed citations
3.
Ngoi, Natalie Y.L., Tuan Zea Tan, Diana Lim, et al.. (2024). Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience. Journal of Gynecologic Oncology. 35(5). e69–e69. 5 indexed citations
4.
Kim, Byoung‐Gie, Chel Hun Choi, Natalie Y.L. Ngoi, David S.P. Tan, & Jae‐Weon Kim. (2024). Preliminary efficacy of pembrolizumab plus lenvatinib in recurrent clear cell gynecological cancer: Phase II LARA trial (GCGS-OV4/APGOT-OV3). P21–P21.
5.
Ngoi, Natalie Y.L., Patrick G. Pilié, Daniel J. McGrail, et al.. (2024). Targeting ATR in patients with cancer. Nature Reviews Clinical Oncology. 21(4). 278–293. 34 indexed citations
6.
Blanc‐Durand, Félix, Natalie Y.L. Ngoi, Étienne Rouleau, et al.. (2024). Unveiling the unique identity of clear-cell endometrial cancer (CCEC): A comprehensive comparative analysis with ovarian counterpart and other endometrial subtypes.. Journal of Clinical Oncology. 42(16_suppl). 5521–5521. 1 indexed citations
7.
8.
Blanc‐Durand, Félix, Christopher M. Kramer, Etienne Rouleau, et al.. (2023). 788P Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches. Annals of Oncology. 34. S529–S530.
9.
Bhamidipati, Deepak, et al.. (2023). PARP inhibitors: enhancing efficacy through rational combinations. British Journal of Cancer. 129(6). 904–916. 86 indexed citations
10.
Ngoi, Natalie Y.L., June‐Yong Lee, Yee Liang Thian, et al.. (2023). LBA8 Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3). Annals of Oncology. 34. S1584–S1584. 1 indexed citations
11.
Ngoi, Natalie Y.L., Heather Lin, Ecaterina E. Dumbrava, et al.. (2023). Abstract 6181: Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials. Cancer Research. 83(7_Supplement). 6181–6181. 2 indexed citations
12.
Tseng, Michelle, et al.. (2022). Combined modality management of advanced cervical cancer including novel sensitizers. International Journal of Gynecological Cancer. 32(3). 246–259. 1 indexed citations
13.
Ngoi, Natalie Y.L., et al.. (2021). The redox-senescence axis and its therapeutic targeting. Redox Biology. 45. 102032–102032. 58 indexed citations
14.
Shi, Yin, et al.. (2021). PRL-3 dephosphorylates p38 MAPK to promote cell survival under stress. Free Radical Biology and Medicine. 177. 72–87. 10 indexed citations
15.
Chia, Daryl Kai Ann, Raghav Sundar, Guowei Kim, et al.. (2021). Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.. Journal of Clinical Oncology. 39(3_suppl). 165–165. 6 indexed citations
16.
Lim, Joline S.J., Joan Choo, Samuel G.W. Ow, et al.. (2021). Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer. Breast Cancer Research and Treatment. 192(1). 131–142. 13 indexed citations
17.
Ngoi, Natalie Y.L., Valerie Heong, Samuel G.W. Ow, et al.. (2020). A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). International Journal of Gynecological Cancer. 30(8). 1239–1242. 16 indexed citations
18.
Ngoi, Natalie Y.L., Valerie Heong, Bok Ai Choo, et al.. (2020). Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01). International Journal of Radiation Oncology*Biology*Physics. 109(3). 701–711. 6 indexed citations
19.
Kim, Guowei, Jingshan Ho, Yvonne Ang, et al.. (2018). Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis. PubMed. 3(3). 20180118–20180118. 20 indexed citations
20.
Ngoi, Natalie Y.L., Valerie Heong, Yiqing Huang, et al.. (2018). Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. Gynecologic Oncology Reports. 24. 1–5. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marilena Di Napoli Breakdown of academic impact, for papers by Anselmo Papa Breakdown of academic impact, for papers by Matin Sheriff Breakdown of academic impact, for papers by Shelly Seward Breakdown of academic impact, for papers by Yoshimichi Tanaka Breakdown of academic impact, for papers by Masanori Kanemura Breakdown of academic impact, for papers by Koji Yamanoi Breakdown of academic impact, for papers by Andrea E. Wahner Hendrickson Breakdown of academic impact, for papers by Katherine C. Kurnit Breakdown of academic impact, for papers by Satoshi Tsunetoh
Rankless by CCL
2026